Group 1 - The company, Zhongzhou Securities, has announced the appointment of Huan Xinhui as the new Deputy General Manager [1] - The appointment was made by the Henan Provincial People's Government according to the official notification [1] - The company will follow relevant laws, regulations, and its articles of association to complete the appointment process and fulfill disclosure obligations [1]

Core Viewpoint - Zhongzhou Securities (01375) announced the appointment of Huaxinhui as the deputy general manager by the Henan Provincial People's Government [1] Group 1 - The appointment is formalized under the notice number Yu Zheng Ren [2025] 127 [1] - The company will follow relevant laws, administrative regulations, and its articles of association to complete the appointment process [1] - The company will fulfill its disclosure obligations accordingly [1]

Group 1 - The core point of the article is the appointment of Huan Xinhui as the Deputy General Manager of Zhongzhou Securities [1] - The appointment was made by the Henan Provincial People's Government, as indicated in the official notification [1] - The company will follow relevant laws, administrative regulations, and its articles of association to complete the appointment process and fulfill disclosure obligations [1]

Group 1 - The company announced the appointment of Huan Xinhui as the deputy general manager [1] - The appointment was made by the Henan Provincial People's Government [1] - The company will follow relevant laws, regulations, and its articles of association to complete the appointment process and fulfill disclosure obligations [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 中原證券股份有限公司 董事長 張秋雲 中國，河南 2025年9月3日 （2002年於中華人民共和國河南省成立的股份有限公司，中文公司名稱為「中原証券股份有限公司」， 在香港以「中州証券」名義開展業務） （股份代號：01375） 收到副總經理任職文件 中原證券股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，近日，本公司 收到河南省人民政府《關於滑欣輝任職的通知》（豫政任〔2025〕127號），任命滑 欣輝先生為本公司副總經理，按《中華人民共和國公司法》和有關規定辦理。本 公司將按照相關法律、行政法規和《公司章程》的規定，盡快履行副總經理聘任 程序，並履行相應披露義務。 承董事會命 Central China Securities Co., Ltd. 於本公告日期，本公司董事為張秋雲女士、李文強先生、馮若凡先生、唐進先生及田聖春先 生，陳志勇先生*、曾崧先生*及賀俊先生*。 * 本公司獨立非執行董事 ...

Group 1 - Zhongyuan Securities experienced a 2.15% decline in stock price, trading at 4.56 yuan per share with a market capitalization of 21.172 billion yuan as of September 3 [1] - The company reported a net outflow of 9.4141 million yuan in main funds, with significant buying and selling activity from large orders [1] - Year-to-date, Zhongyuan Securities' stock price has increased by 5.97%, with a 1.30% decline over the last five trading days [1] Group 2 - As of June 30, Zhongyuan Securities had 120,400 shareholders, a decrease of 3.84% from the previous period, while the average number of circulating shares per person increased by 3.99% [2] - For the first half of 2025, the company reported zero operating revenue but a net profit attributable to shareholders of 260 million yuan, representing a year-on-year growth of 29.34% [2] Group 3 - Since its A-share listing, Zhongyuan Securities has distributed a total of 1.472 billion yuan in dividends, with 204 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders included the Guotai Zhongzheng All-Index Securities Company ETF, which reduced its holdings by 4.443 million shares [3]

Group 1: Lithium Battery Industry Overview - China's lithium battery and new energy vehicle industries have significant global competitiveness, with the lithium battery sector's valuation notably below the industry median level of 44.41 times since 2013 [1] - The lithium battery segment is expected to generate revenue of 2.25 trillion yuan in 2024, with a compound annual growth rate (CAGR) of 21.80% from 2018 to 2024, despite a substantial decline in net profit projected for 2023-2024 [1] - Key issues in the lithium battery industry include a mismatch between net profit scale and global industry position, overall low profitability, and excess capacity due to continuous release of production capacity in the segmented fields [1] Group 2: New Energy Vehicle Industry Overview - Since 2009, China's automotive production and sales have ranked first globally, with projections indicating over 30 million units produced and sold in 2024, making China the largest automobile exporter [2] - The new energy vehicle sector has maintained a leading position globally, with sales expected to reach 12.859 million units in 2024, a year-on-year increase of 36.10%, accounting for 40.92% of total new energy vehicle sales in China [2] - Despite growth in production and sales, the overall profitability of the automotive industry remains low, with projected profits of 462.3 billion yuan in 2024, significantly lower than the peak profit of 688.3 billion yuan in 2017 [2] Group 3: Policy Measures Against "Involution" Competition - The Chinese government has initiated a series of macro policies to address "involution" competition, with the central political bureau emphasizing the need to prevent such competition for the first time in July 2024 [3] - Various government bodies and industry associations have introduced self-regulatory initiatives and policies aimed at enhancing the global competitiveness of the new energy vehicle and lithium battery industries [3] - The comprehensive measures against involution are expected to further strengthen the global competitiveness of China's new energy vehicle and lithium battery sectors [3]

Core Viewpoint - Zhongyuan Media has shown strong financial performance in H1 2025, with significant increases in net profit and effective cost control measures leading to improved profitability [2][3]. Financial Performance - In H1 2025, Zhongyuan Media achieved operating revenue of 4.575 billion yuan, a year-on-year increase of 1.00%, and a net profit attributable to shareholders of 532 million yuan, up 50.39% year-on-year [2]. - For Q2 2025, the company reported operating revenue of 2.659 billion yuan, a year-on-year increase of 0.97% and a quarter-on-quarter increase of 38.76%, with a net profit of 422 million yuan, up 31.51% year-on-year and 283.55% quarter-on-quarter [2]. Cost Control and Profitability - The reduction in income tax expenses and effective cost management contributed to the performance improvement, with the gross margin at 38.14%, a slight increase of 0.13 percentage points year-on-year, and a significant rise in net margin from 8.02% to 11.97% [3]. - Sales and management expenses decreased by 9.68% and 8.20% year-on-year, respectively, leading to a decline in expense ratios [3]. Business Segmentation - The publishing segment generated 1.564 billion yuan in revenue, a slight decrease of 0.41%, while the distribution segment saw a revenue increase of 0.19% to 3.692 billion yuan [3]. - The printing business experienced a significant decline in revenue by 41.35%, but its impact on overall performance was minimal due to its smaller scale [3]. Innovation and Digital Transformation - The company has enhanced its content innovation capabilities, with 45 projects receiving national and provincial awards, and 85 books achieving copyright exports [4]. - Digital platforms have seen significant growth, with "Shuxiang Henan" and "Baixing Cultural Cloud" platforms recording 27.65 million new views and 82,500 new users [4][5]. Strategic Business Development - Zhongyuan Media is expanding its innovative business layout, with 278 innovative product offerings and 68 approved after-school service courses [6]. - The integration of smart education, after-school services, and research-based practices is forming a comprehensive service ecosystem [6]. Profit Forecast - The projected net profits for 2025, 2026, and 2027 are 1.319 billion yuan, 1.390 billion yuan, and 1.407 billion yuan, respectively, with corresponding PE ratios of 10.10, 9.58, and 9.47 [6].

截至2025年8月29日收盘，中原证券（601375）报收于4.66元，较上周的4.77元下跌2.31%。本周，中原 证券8月25日盘中最高价报4.9元。8月28日盘中最低价报4.55元。中原证券当前最新总市值216.36亿元， 在证券板块市值排名45/50，在两市A股市值排名873/5152。 中原证券2025年中报显示，主营收入9.21亿元，同比下降23.14%；归母净利润2.6亿元，同比上升 29.14%；扣非净利润2.53亿元，同比上升28.35%。2025年第二季度单季度主营收入5.2亿元，同比下降 6.2%；单季度归母净利润1.57亿元，同比上升123.26%；单季度扣非净利润1.55亿元，同比上升 118.81%。负债率为72.96%，投资收益为2.75亿元。 公司公告汇总 中原证券拟以实施权益分派股权登记日登记的总股本为基数，向全体股东每10股派发现金红利0.08元 （含税），合计拟派发现金红利37,143,077.60元（含税），占上半年归母净利润的14.27%。现金红利以 人民币计值，A股股东以人民币支付，H股股东以港币支付，汇率按董事会召开日前五个工作日人民币 兑港币平均基准汇率计算。不 ...

Core Viewpoint - The report highlights the strong performance of the pet segment and the impact of new product launches on the company's revenue growth, leading to an "overweight" rating for the company. Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 559 million yuan, a year-on-year increase of 15.79% [1] - The net profit attributable to shareholders reached 116 million yuan, up 57.12% year-on-year, while the net profit after deducting non-recurring gains and losses was 100 million yuan, reflecting a growth of 50.79% [1] - The net cash flow from operating activities was 195 million yuan, showing a significant increase of 305.09% year-on-year [1] - In Q2 2025, the company reported operating revenue of 281 million yuan, a year-on-year increase of 13.38%, and a net profit of 63 million yuan, up 35.67% year-on-year [1] Group 2: Product Performance - Revenue from various product segments in H1 2025 included: - Pig vaccines: 131 million yuan, down 11.49% year-on-year - Poultry vaccines and antibodies: 259 million yuan, up 30.01% year-on-year - Ruminant vaccines: 1.68 million yuan, up 39.62% year-on-year - Pet vaccines: 10.07 million yuan, up 49.65% year-on-year - Chemical drugs: 124 million yuan, up 20.94% year-on-year - Pet chemical drugs: 8.37 million yuan, up 9.99% year-on-year - Pet health products: 128.14 million yuan, up 124.47% year-on-year [2] - The new production base in Nanjing has been fully operational, leading to a nearly 60% increase in sales revenue from high-pathogenic avian influenza vaccines [2] - The company continues to implement a dual-channel marketing strategy for pet products, with online sales increasing by over three times [2] Group 3: Cost Control and R&D - The company's gross margin was 59.76%, a decrease of 3.42 percentage points year-on-year, while the net profit margin was 20.77%, down 5.47 percentage points year-on-year [3] - The company received 8 new veterinary drug registration certificates and 4 invention patent authorizations in H1 2025, indicating strong R&D capabilities [3] - Despite the decrease in margins, the company maintained a high level of R&D investment while enhancing cost control through economies of scale [3] Group 4: Future Outlook and Valuation - The company maintains a profit forecast of 178 million yuan, 197 million yuan, and 232 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.52, 0.57, and 0.67 yuan [3] - The current stock price corresponds to PE ratios of 28.70, 26.02, and 22.04 for the next three years, indicating a reasonable valuation range compared to peer companies [3] - The company's leading R&D innovation capabilities suggest potential for future valuation expansion [3]